Neurosona Signs Business Agreement with Predictive Care

Development of Alzheimer’s Diagnosis and Treatment Technologies

Neurosona Co., Ltd. announced on the 3rd that it has signed a Memorandum of Understanding (MOU) for business cooperation with Predictiv Care for the development of Alzheimer's diagnosis, prediction, treatment, and learning ability enhancement technologies. According to this MOU, both companies plan to collaborate on the technologies they possess.

Neurosona is currently conducting clinical trials applying its 'Low-Intensity Focused Ultrasound Stimulation System' to patients with various brain disorders such as depression, Alzheimer's, sleep disorders, and stroke. Neurosona's 'Low-Intensity Focused Ultrasound Stimulation System' was designated as an innovative medical device by the Ministry of Food and Drug Safety in August 2021, recognizing its innovative technology and potential for clinical improvement.

Predictiv Care, Inc., based in North America, is a company developing digital twin solutions based on genomic analysis. They have developed technology that predicts disease onset probability and drug sensitivity using a digital twin (a digital virtual world replicating the real state) containing genomic analysis information.

Predictiv Care has attracted investments from Silicon Valley venture capital (VC), Naver, Hana Securities, and Muir Woods Ventures, recognizing its technological capabilities and business potential.

Seonil Seo, CEO of Neurosona, stated, "Through collaboration with Predictiv Care, we aim to analyze the causes of Alzheimer's disease and develop methods to predict its onset." He added, "By analyzing brain function with Predictiv Care's technology and integrating it into Neurosona's home-use ultrasound stimulator 'Neurocon' under development, individuals will be able to improve functions necessary for learning even at home."